Clinical Scorecard: Forecasting Complications for Risk Assessment of Chemotherapy-Induced Stem Cell Mobilization in Multiple Myeloma

At a Glance

Key Highlights

• 97% of patients achieved successful stem-cell collection despite high incidence of severe adverse events (69%) requiring hospitalization.
• Machine learning models can predict certain adverse events (e.g., elevated creatinine with ROC-AUC 1.0) and forecast timing of adverse event onset with a mean error of about one day.
• Risk-stratified outpatient stem-cell mobilization protocols could reduce inpatient bed usage by at least one third without compromising patient safety.

Guideline-Based Recommendations

Diagnosis

• Assess eligibility for autologous stem-cell transplantation in multiple myeloma patients.
• Monitor renal function and neutropenic fever risk during stem-cell mobilization.

Management

• Consider inpatient chemotherapy-based stem-cell mobilization as standard care.
• Implement risk-stratified outpatient mobilization protocols guided by predictive modeling to optimize resource use and patient safety.

Monitoring & Follow-up

• Closely monitor for severe adverse events requiring hospitalization during mobilization.
• Use predictive models to anticipate adverse event onset timing for optimized ward management.

Risks

• High incidence of severe adverse events (69%) including neutropenic fever and elevated creatinine.
• Challenges remain in accurately predicting neutropenic fever (ROC-AUC 0.67).

Patient & Prescribing Data

109 multiple myeloma patients undergoing chemotherapy-based stem-cell mobilization

High success rate of stem-cell collection with significant risk of severe adverse events; predictive analytics can guide safe outpatient mobilization.

Clinical Best Practices

• Use machine learning risk stratification to identify patients suitable for outpatient stem-cell mobilization.
• Maintain inpatient care for high-risk patients to manage severe adverse events promptly.
• Integrate predictive timing of adverse events into clinical workflows to optimize hospital resource allocation.

References

• Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2024.
• Pompa A et al. Outpatient stem cell mobilization with intermediate-dose cyclophosphamide is a safe and effective procedure. Blood. 2016.
• Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2012.
• Martino M et al. Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art. Front. Oncol. 2020.
• Larsen K et al. Feasibility of outpatient autologous stem cell transplantation in multiple myeloma and risk factors predicting hospital admission. Blood. 2020.